In conclusion, our work reveals an important role of A2B in mediating Olaparib resistance in ovarian cancer cells by activating IL‐6‐STAT3 signalling pathway, highlighting a novel application of A2B and STAT3 inhibition in defeating Olaparib resistance. This evidence concerns the gene STAT3 and ovarian carcinoma.